A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
NCT01288989
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
BIOLOGICAL:
IMC-3C5
Sponsor
Eli Lilly and Company